Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Statera BioPharma

Why Snap Shares Are Trading Sharply Lower; Here Are 25 Stocks Moving Premarket

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 40.9% to $0.2160 in pre-market trading. Statera Biopharma recently signed a binding Memorandum of Understanding with Holobeam Technologies Inc.

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Inventiva (NASDAQ:IVA) shares increased by 44.0% to $5.88 during Friday's regular session. The market value of their outstanding shares is at $247.6 million.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of Radiation-Related Disorders."

Why WISeKey International Is Trading Higher By Over 20%; Here Are 29 Stocks Moving Premarket

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 89.4% to $0.2655 in pre-market trading. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of Radiation-Related Disorders."

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

Here's a roundup of top developments in the biotech space over the last 24 hours:

12 Health Care Stocks Moving In Friday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform

Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform

Coeptis Therapeutics Inc (OTC:COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ:STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5) agonist platform, including entolimod. Coeptis will agree to pay Statera Biopharma $6 million and revenue-based milestone payments to be defined in the definitive agreement. TLR5 is an innate immunity…

Stocks That Hit 52-Week Lows On Tuesday

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 81 stocks hit new 52-week lows.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Stocks That Hit 52-Week Lows On Tuesday

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 52 companies set new 52-week lows.

24 Stocks Moving in Friday's Pre-Market Session

24 Stocks Moving in Friday's Pre-Market Session

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 30.4% to $0.9520 in pre-market trading. Statera Biopharma recently submitted Phase 1 clinical trial protocol to the FDA for investigational treatment of long-haul COVID-19.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Blackrock Muniholdings

Genocea Biosciences

Statera BioPharma

Quoin Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play